Aditxt
Open
$0.01
Prev. Close
$0.01
High
$0.01
Low
$0.01
Market Snapshot
$365.14
-0.0
-33454.44
$133.99K
26
Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. The company is headquartered in Richmond, Virginia and currently employs 26 full-time employees. The company went IPO on 2020-06-19. The firm operates four programs focused on autoimmunity, cancer and early disease detection, infectious diseases and women’s health. Its subsidiaries include Adimune, Inc. (Adimune), Pearsanta, Inc., Adivir, Inc. and Adifem, Inc. Adimune is focused on its immune modulation therapeutic programs. Adimune’s proprietary immune modulation product, Apoptotic DNA Immunotherapy (ADI), utilizes a novel approach that mimics the way its bodies naturally induce tolerance to our own tissues. Adivir, Inc. is focused on building a portfolio of antiviral and other antimicrobial solutions designed to target life-threatening viral infections and emerging pathogens. Pearsanta, Inc. is engaged in the development of molecular tests based on mitochondrial DNA to develop tests for early detection of cancer. The company is also focused on addressing a critical challenge in cancer care: optimizing therapy selection.
Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. The company is headquartered in Richmond, Virginia and currently employs 26 full-time employees. The company went IPO on 2020-06-19. The firm operates four programs focused on autoimmunity, cancer and early disease detection, infectious diseases and women’s health. Its subsidiaries include Adimune, Inc. (Adimune), Pearsanta, Inc., Adivir, Inc. and Adifem, Inc. Adimune is focused on its immune modulation therapeutic programs. Adimune’s proprietary immune modulation product, Apoptotic DNA Immunotherapy (ADI), utilizes a novel approach that mimics the way its bodies naturally induce tolerance to our own tissues. Adivir, Inc. is focused on building a portfolio of antiviral and other antimicrobial solutions designed to target life-threatening viral infections and emerging pathogens. Pearsanta, Inc. is engaged in the development of molecular tests based on mitochondrial DNA to develop tests for early detection of cancer. The company is also focused on addressing a critical challenge in cancer care: optimizing therapy selection.
Recently from Cashu
Aditxt Enhances Immune Health Innovations and Expands Focus to Precision Health Solutions
Aditxt Expands Focus on Immune and Precision Health Innovations Aditxt, Inc., a California-based social innovation platform, is making strides in the field of immune health through its subsidiaries, p…
Aditxt's Strategic Innovations in Health: Focus on Autoimmune and Cancer Detection Solutions
Aditxt's Strategic Expansion in Health Innovations Aditxt, Inc., a social innovation platform based in Mountain View, California, is poised to enhance its position in the health innovation sector thro…
Aditxt's Pearsanta Targets Cancer Diagnostics with Upcoming IPO for Innovative Solutions
Aditxt Paves the Way for Cancer Diagnostics Innovation Aditxt, Inc., a social innovation platform dedicated to advancing health technologies, is making significant strides in the realm of precision di…
Aditxt Pursues IPO for Pearsanta to Enhance Cancer Diagnostics and Health Innovations
Aditxt's Strategic Initiative to Amplify Cancer Diagnostics Through IPO Aditxt, Inc. takes a significant step towards enhancing its health innovation platform by authorizing its Board of Directors to…